These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 20005515)
1. The effect of PPAR-alpha agonism on apolipoprotein metabolism in humans. Shah A; Rader DJ; Millar JS Atherosclerosis; 2010 May; 210(1):35-40. PubMed ID: 20005515 [TBL] [Abstract][Full Text] [Related]
2. Potent and selective PPAR-alpha agonist LY518674 upregulates both ApoA-I production and catabolism in human subjects with the metabolic syndrome. Millar JS; Duffy D; Gadi R; Bloedon LT; Dunbar RL; Wolfe ML; Movva R; Shah A; Fuki IV; McCoy M; Harris CJ; Wang MD; Howey DC; Rader DJ Arterioscler Thromb Vasc Biol; 2009 Jan; 29(1):140-6. PubMed ID: 18988892 [TBL] [Abstract][Full Text] [Related]
3. Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity. Ooi EM; Watts GF; Sprecher DL; Chan DC; Barrett PH J Clin Endocrinol Metab; 2011 Oct; 96(10):E1568-76. PubMed ID: 21816786 [TBL] [Abstract][Full Text] [Related]
4. Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials. Nissen SE; Nicholls SJ; Wolski K; Howey DC; McErlean E; Wang MD; Gomez EV; Russo JM JAMA; 2007 Mar; 297(12):1362-73. PubMed ID: 17384435 [TBL] [Abstract][Full Text] [Related]
5. Potent peroxisome proliferator-activated receptor-α agonist treatment increases cholesterol efflux capacity in humans with the metabolic syndrome. Khera AV; Millar JS; Ruotolo G; Wang MD; Rader DJ Eur Heart J; 2015 Nov; 36(43):3020-2. PubMed ID: 26112886 [TBL] [Abstract][Full Text] [Related]
6. Very low density lipoprotein metabolism and plasma adiponectin as predictors of high-density lipoprotein apolipoprotein A-I kinetics in obese and nonobese men. Chan DC; Barrett PH; Ooi EM; Ji J; Chan DT; Watts GF J Clin Endocrinol Metab; 2009 Mar; 94(3):989-97. PubMed ID: 19116237 [TBL] [Abstract][Full Text] [Related]
7. Identification of a novel selective peroxisome proliferator-activated receptor alpha agonist, 2-methyl-2-(4-{3-[1-(4-methylbenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl]propyl}phenoxy)propanoic acid (LY518674), that produces marked changes in serum lipids and apolipoprotein A-1 expression. Singh JP; Kauffman R; Bensch W; Wang G; McClelland P; Bean J; Montrose C; Mantlo N; Wagle A Mol Pharmacol; 2005 Sep; 68(3):763-8. PubMed ID: 15933217 [TBL] [Abstract][Full Text] [Related]
8. Interrelationships between human apolipoprotein A-I and apolipoproteins B-48 and B-100 kinetics using stable isotopes. Welty FK; Lichtenstein AH; Barrett PH; Dolnikowski GG; Schaefer EJ Arterioscler Thromb Vasc Biol; 2004 Sep; 24(9):1703-7. PubMed ID: 15242863 [TBL] [Abstract][Full Text] [Related]
9. Combining beta-adrenergic and peroxisome proliferator-activated receptor gamma stimulation improves lipoprotein composition in healthy moderately obese subjects. Hughes TA; Stentz F; Gettys T; Smith SR Metabolism; 2006 Jan; 55(1):26-34. PubMed ID: 16324916 [TBL] [Abstract][Full Text] [Related]
11. Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism. Fruchart JC; Duriez P Drugs Today (Barc); 2006 Jan; 42(1):39-64. PubMed ID: 16511610 [TBL] [Abstract][Full Text] [Related]
12. Apolipoprotein A-I and B levels, dyslipidemia and metabolic syndrome in south-west Chinese women with PCOS. Zhang J; Fan P; Liu H; Bai H; Wang Y; Zhang F Hum Reprod; 2012 Aug; 27(8):2484-93. PubMed ID: 22674204 [TBL] [Abstract][Full Text] [Related]
13. TRL, IDL, and LDL apolipoprotein B-100 and HDL apolipoprotein A-I kinetics as a function of age and menopausal status. Matthan NR; Jalbert SM; Lamon-Fava S; Dolnikowski GG; Welty FK; Barrett HR; Schaefer EJ; Lichtenstein AH Arterioscler Thromb Vasc Biol; 2005 Aug; 25(8):1691-6. PubMed ID: 15933247 [TBL] [Abstract][Full Text] [Related]
14. Interrelationships between the kinetics of VLDL subspecies and HDL catabolism in abdominal obesity: a multicenter tracer kinetic study. Vergès B; Adiels M; Boren J; Barrett PH; Watts GF; Chan D; Duvillard L; Söderlund S; Matikainen N; Kahri J; Robin I; Taskinen MR J Clin Endocrinol Metab; 2014 Nov; 99(11):4281-90. PubMed ID: 25077901 [TBL] [Abstract][Full Text] [Related]
15. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Staels B; Dallongeville J; Auwerx J; Schoonjans K; Leitersdorf E; Fruchart JC Circulation; 1998 Nov; 98(19):2088-93. PubMed ID: 9808609 [TBL] [Abstract][Full Text] [Related]
16. Apolipoprotein A-II and adiponectin as determinants of very low-density lipoprotein apolipoprotein B-100 metabolism in nonobese men. Chan DC; Watts GF; Ooi EM; Chan DT; Wong AT; Barrett PH Metabolism; 2011 Oct; 60(10):1482-7. PubMed ID: 21550083 [TBL] [Abstract][Full Text] [Related]
17. ApoB but not LDL-cholesterol is reduced by exercise training in overweight healthy men. Results from the 1-year randomized Oslo Diet and Exercise Study. Holme I; Høstmark AT; Anderssen SA J Intern Med; 2007 Aug; 262(2):235-43. PubMed ID: 17645591 [TBL] [Abstract][Full Text] [Related]
18. Apolipoprotein B-100 kinetics and static plasma indices of triglyceride-rich lipoprotein metabolism in overweight men. Chan DC; Watts GF; Ng TW; Uchida Y; Sakai N; Yamashita S; Barrett PH Clin Biochem; 2005 Sep; 38(9):806-12. PubMed ID: 15992790 [TBL] [Abstract][Full Text] [Related]